List view / Grid view

News

European Commission approves Bristol-Myers Squibb’s Daklinza (daclatasvir) across multiple genotypes for the treatment of chronic hepatitis C infection

27 August 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults...

GSK receives FDA approval of an additional Promacta® (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST)

27 August 2014 | By GlaxoSmithKline

GlaxoSmithKline plc announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the once-daily use of Promacta® (eltrombopag) in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy...

Actavis confirms Generic Neupro® Patent challenge

26 August 2014 | By Actavis

Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr...

Novartis provides drug candidate compounds to TB Alliance

20 August 2014 | By Novartis

Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development for compounds to fight tuberculosis that have been discovered at the Novartis Institutes for Tropical Diseases...